Testing a new gene therapy injection for vision loss from macular degeneration

Plain-English translation of NCT06765980 on ClinicalTrials.gov ↗ · Source last updated August 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

This is one of the first times this treatment has been tested in people.

What is this trial?

This trial is testing KRIYA-825 (VV-14295), a new gene therapy delivered as a single injection into the eye. The medication is designed to slow or stop the growth of geographic atrophy—areas of vision loss caused by age-related macular degeneration. Researchers want to find out if this treatment is safe and whether it can help preserve your remaining vision.

Geographic atrophy causes progressive, permanent vision loss and currently has no approved treatment that can stop it from getting worse. This trial is exploring whether this medication could offer hope to patients by slowing the disease's progression.

Do you qualify?

You likely qualify if…

you are between 55 and 80 years old
you have been diagnosed with geographic atrophy secondary to age-related macular degeneration in one eye
you have specific vision loss levels in your affected eye and your other eye is healthier or equally healthy
you have a body mass index between 19 and 34
you are willing to use reliable contraception for at least 12 months after receiving the injection
your eye is clear enough to allow good quality imaging during the study

You likely don't qualify if…

you have other eye diseases or conditions besides geographic atrophy from macular degeneration
you have a history of wet age-related macular degeneration or abnormal blood vessel growth in either eye
you have had eye surgery such as vitrectomy or a corneal transplant in your study eye
you have an active or recent eye infection or inflammation that is not controlled
you cannot take steroid medications (oral or eye drops) or have medical conditions that make steroid treatment risky for you

What participation looks like

You will receive a single injection of the medication into your eye on Day 1, using a special injector device. Before and after the injection, you'll take oral steroid medication and use steroid eye drops to reduce inflammation—switching to a different eye drop after a few weeks. You'll then have regular follow-up visits over 12 months to monitor your eye health, vision, and any side effects through eye exams and imaging.

AI-generated summary from trial data · Aug 26, 2026 · Not medical advice

Trial locations(4 sites)

United States

Kriya Clinical Study Site, Erie, Pennsylvania

Canada

Kriya Clinical Study Site, Ottawa, Ontario

Israel

Kriya Clinical Study Site, Tel Aviv

New Zealand

Kriya Clinical Study Site, Christchurch